A Phase 1/2, Open-label, Multi-center Study of the Safety and Efficacy of Alomfilimab (KY1044) as Single Agent and in Combination With Anti-PD-L1 (Atezolizumab) in Adult Patients With Selected Advanced Malignancies

Clinical trial NCT03829501 · TERMINATED

Trial details

NCT number: NCT03829501
Sponsor: Kymab Limited
Status: TERMINATED
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Squamous Cell Carcinoma of Head and Neck Non-small Cell Lung Cancer Hepatocellular Carcinoma Esophageal Cancer Gastric Cancer Melanoma Renal Cell Carcinoma Pancreatic Cancer Cervical Cancer Triple Negative Breast Cancer Advanced Cancer Metastatic Cancer

Start date: 2019-01-28
Primary completion: 2024-10-03
Enrollment: 222

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.